AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of January 9, 2026, AVTX stock price declined to $16.95 with 167,801 million shares trading.

AVTX has a beta of 1.47, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.09 to the broad based SPY ETF.

AVTX has a market cap of $307.37 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,295.90 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAS.

AVTX has outperformed the market in the last year with a return of +141.1%, while the SPY ETF gained +19.0%. In the last 3 month period, AVTX beat the market returning +13.2%, while SPY returned +3.7%. However, in the most recent 2 weeks AVTX has underperformed the stock market by returning -7.7%, while SPY returned +0.5%.

AVTX support price is $16.26 and resistance is $17.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.